Adolescents with Human Immunodeficiency Virus (HIV) in Botswana, South Africa, Thailand, Uganda and the United States who received the injectable intramuscular antiviral medications cabotegravir and rilpivirine for nearly a year after being switched from daily oral HIV medications, which they had been on most of their life, experienced no major safety concerns, had continued viral suppression and greatly preferred the new treatment method.
This article was originally published on MedicalXpress.com
